RA Capital Management, L.P. 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-23 4:29 pm Purchase | 2026-04-22 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA Capital Management, L.P. | 12,284,906 28.800% | 3,888,888 (+46.32%) | Filing |
| 2026-03-23 4:28 pm Purchase | 2026-03-19 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA Capital Management, L.P. | 8,396,018 21.600% | 36,916 (+0.44%) | Filing |
| 2024-04-11 4:16 pm Purchase | 2024-04-11 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA Capital Management, L.P. | 8,359,102 27.100% | 3,541,743 (+73.52%) | Filing |
| 2023-03-30 5:07 pm Purchase | 2023-03-28 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA Capital Management, L.P. | 4,817,359 22.000% | 3,917 (+0.08%) | Filing |
| 2022-11-28 4:31 pm Purchase | 2022-11-17 | 13D | ACRIVON THERAPEUTICS INC ACRV | RA Capital Management, L.P. | 4,813,442 23.070% | 4,813,442 (New Position) | Filing |